TIANFU Ozagrel

Details:

Product Name: Ozagrel
Synonyms: (E)-4-(1-Imidazoylmethyl)cinnamic acid;2-Propenoic acid, 3-[4-(1H-imidazol-1-ylmethyl)phenyl]-, (2E)-;(E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]propenoic acid;(E)-3-[p-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid;Ozagrel API;Ozagrel(OKY-046);(2E)-3-[4-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid;(E)-3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enoic acid
CAS: 82571-53-7
MF: C13H12N2O2
MW: 228.25
EINECS: 242-903-4
Product Categories: Inhibitors;Cardiovascular Series;Cardiovascular;Pharmaceutical material and intermeidates
Mol File: 82571-53-7.mol
Ozagrel Structure
Ozagrel Chemical Properties
Melting point  223-224°
CAS DataBase Reference 82571-53-7(CAS DataBase Reference)

Ozagrel Usage And Synthesis
Platelet aggregation inhibitor Ozagrel and clopidogrel, cilostazol, aspirin enteric-coated tablets are commonly used in China at present as platelet aggregation inhibitor, Ozagrel is an anti-thrombosis drug which belongs to a thromboxane alkyl cyclooxygenase (TXA2) inhibitors, originally it was successfully developed by Japan Ono pharmaceutical Co., Ltd. and Kissei pharmaceutical Co., Ltd. ,it was approved for marketing in Japan in 1988. At present, domestic manufacturers include the Liaoning dandong, medical and pharmaceutical industry, Shandong Elohim Pharmaceutical Co., Changchun fine distinctions Pharmaceutical, Dalian Metro big pharmaceutical companies, pharmaceutical Shenyang Jishi, Hainan bikai Pharmaceutical, Changchun Haobang Pharmaceutical and Shandong HuaLu pharmaceutical. Modern medicine has proved that platelets play an important role in the process of atherosclerosis and thrombosis, the effective regulation of platelet can play a multiplier effect on blood vessel lumen stenosis, emboli and diseases caused by occlusion of blood circulatory system . At present, the platelet aggregation inhibitor drugs used clinically are mainly cyclooxygenase (TXA2) inhibitors, phosphodiesterase (PDE) inhibitors, adenosine diphosphate (ADP) receptor antagonists, platelet fibrinogen antagonists drugs.